New combo therapy shows promise for Hard-to-Treat myeloma
NCT ID NCT07084896
First seen May 11, 2026 · Last updated May 11, 2026
Summary
This study is for people with multiple myeloma that has come back or stopped responding to at least three prior treatments. It tests a combination of two drugs—belantamab mafodotin and nirogacestat—to see if they are safe and can shrink or control the cancer. About 106 adults will take part, and the goal is to find the best dose and measure how many patients respond.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
238995
Atlanta, Georgia, 30322, United States
-
239015
Madison, Wisconsin, 53792, United States
-
240593
Boston, Massachusetts, 02215, United States
-
251164
Grand Rapids, Michigan, 49546, United States
-
GSK Investigational Site
Fitzroy, Victoria, 3065, Australia
-
GSK Investigational Site
Vancouver, British Columbia, V5Z1M9, Canada
-
GSK Investigational Site
Halifax, Nova Scotia, B3H 1V7, Canada
-
GSK Investigational Site
Lille, 59037, France
-
GSK Investigational Site
Villejuif, 94805, France
-
GSK Investigational Site
Frankfurt, 60590, Germany
-
GSK Investigational Site
Kiel, 24105, Germany
-
GSK Investigational Site
Leipzig, 04103, Germany
-
GSK Investigational Site
Athens, 11528, Greece
-
GSK Investigational Site
Utrecht, 3584 CX, Netherlands
-
GSK Investigational Site
Oslo, 0450, Norway
-
GSK Investigational Site
Katowice, 40-519, Poland
-
GSK Investigational Site
Lodz, 93-513, Poland
-
GSK Investigational Site
Lublin, 20-081, Poland
-
GSK Investigational Site
Moscow, 125284, Russia
-
GSK Investigational Site
Incheon, 21565, South Korea
-
GSK Investigational Site
Seoul, 06351, South Korea
-
GSK Investigational Site
Seoul, 06591, South Korea
-
GSK Investigational Site
Ulsan, 44033, South Korea
-
GSK Investigational Site
Badalona, 08916, Spain
-
GSK Investigational Site
Madrid, 28041, Spain
-
GSK Investigational Site
Madrid, 31008, Spain
-
GSK Investigational Site
Pozuelo de AlarcOn Madr, 28223, Spain
-
GSK Investigational Site
Falun, SE-791 82, Sweden
-
GSK Investigational Site
Stockholm, SE-141 86, Sweden
Conditions
Explore the condition pages connected to this study.